StockData
Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc. (ALZN) stock

ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.13−0.05 (-4.24%)

Close on Nov 17, 2026Market cap $5.45MP/E –Yield –

Alzamend Neuro r&d expenses

Research and development expenses are spending on new products and technology.

Alzamend Neuro's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.97M. For fiscal 2026 it was $3.63M, up 156.5% from the year before. The highest annual figure on record is $7.45M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Apr 30, 2026$3.63M+156.5%
FY2025Apr 30, 2025$1.41M-78.1%
FY2024Apr 30, 2024$6.46M-13.3%
FY2023Apr 30, 2023$7.45M+43.2%
FY2022Apr 30, 2022$5.20M+296.8%
FY2021Apr 30, 2021$1.31M+22.6%
FY2020Apr 30, 2020$1.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026$1.09M-37.6%
Q4 FY2026CQ1 2026Apr 30, 2026$434.01K+110.1%
Q3 FY2026CQ4 2025Jan 31, 2026$1.28M+597.1%
Q2 FY2026CQ3 2025Oct 31, 2025$176.28K-90.8%
Q1 FY2026CQ2 2025Jul 31, 2025$1.74M-12.8%
Q1 FY2025CQ2 2024Jul 31, 2024$206.57K-91.3%
Q4 FY2024CQ1 2024Apr 30, 2024$183.43K-88.9%
Q3 FY2024CQ4 2023Jan 31, 2024$1.91M-33.9%
Q2 FY2024CQ3 2023Oct 31, 2023$2.00M+30.3%
Q1 FY2024CQ2 2023Jul 31, 2023$2.37M+72.0%
Q4 FY2023CQ1 2023Apr 30, 2023$1.65M-0.8%
Q3 FY2023CQ4 2022Jan 31, 2023$2.89M+230.7%
Q2 FY2023CQ3 2022Oct 31, 2022$1.53M-12.4%
Q1 FY2023CQ2 2022Jul 31, 2022$1.38M+50.1%
Q4 FY2022CQ1 2022Apr 30, 2022$1.66M+467.6%
Q3 FY2022CQ4 2021Jan 31, 2022$873.65K+272.9%
Q2 FY2022CQ3 2021Oct 31, 2021$1.75M+268.5%
Q1 FY2022CQ2 2021Jul 31, 2021$916.41K+196.7%
Q4 FY2021CQ1 2021Apr 30, 2021$292.70K–
Q3 FY2021CQ4 2020Jan 31, 2021$234.26K–
Q2 FY2021CQ3 2020Oct 31, 2020$474.91K–
Q1 FY2021CQ2 2020Jul 31, 2020$308.85K–

More Alzamend Neuro figures

See a number that looks wrong?